Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals
for the treatment of neurological and endocrine-related diseases and
disorders in the United States. The company’s products in clinical
development stage include elagolix, which is in Phase III study for
endometriosis; elagolix that is in Phase IIb study for uterine fibroids;
Corticotropin-Releasing Factor Receptor1 Antagonist, which is in Phase
I/II study for congenital adrenal hyperplasia and stress-related
disorders; and Vesicular Monoamine Transporter 2 Inhibitor (VMAT2) that
is in Phase III study for movement disorders, as well as Phase I study
for tourette syndrome. Its research programs comprise VMAT2 for movement
disorders, bipolar disorders, and schizophrenia; gonadotropin-releasing
hormone (GnRH) antagonists for men’s and women’s health, and oncology;
antiepileptic drugs for epilepsy, essential tremor, and pain; and G
Protein-Coupled receptors for other conditions. The company also
develops pharmaceutical products for tardive dyskinesia, and other
neurological and endocrine-related diseases and disorders.
Take a look at the 1-year chart of Neurocrine (NASDAQ: NBIX) below with added notations:
NBIX started from a $12 low back in July of last year and rallied
from that low up to a $45 high in March. From there, the stock hit $45
as resistance a few more times forming a solid 52-week high resistance
at $45 (blue). Last week the stock broke through that level, which
should lead to higher prices overall.
The Tale of the Tape: NBIX broke its 52-week
resistance at $45. The possible long position on the stock would be on a
pullback down to that level with a stop placed under it. A break back
below $45 could negate the forecast for a move higher.
Please share this article
No comments:
Post a Comment